EULAR 2022 Congress

News and expert insight from the 2022 European Congress of Rheumatology | June 1 – 4

EULAR 2022 Congress highlights

04-06-2022 | EULAR 2022 | Conference coverage | News

Bimekizumab beneficial for psoriatic arthritis in phase 3 trials

Bimekizumab has shown positive efficacy and safety results in the BE COMPLETE and BE OPTIMAL phase 3 psoriatic arthritis trials.

04-06-2022 | EULAR 2022 | Conference coverage | News

Support for pausing methotrexate only after second COVID-19 vaccine dose

Pausing methotrexate only after the second dose of a COVID-19 vaccine may provide the best balance between antibody response and risk for flare, findings from two randomized controlled trials suggest.

03-06-2022 | EULAR 2022 | Conference coverage | News

The EULAR 2022 Debate: Will COVID-19 have a long-term impact on rheumatology practice?

At the EULAR 2022 Congress in Copenhagen, Denmark, two experts debated whether COVID-19 will have a lasting effect on rheumatology clinical practice.

03-06-2022 | EULAR 2022 | Conference coverage | News

Chronic, low-dose glucocorticoid benefits outweigh harms in senior patients with RA

Findings from the GLORIA trial suggest that older patients with established rheumatoid arthritis could benefit from 2 years of low-dose glucocorticoids in addition to their existing disease-modifying treatment with a favorable balance of benefit and harm.

01-06-2022 | EULAR 2022 | Conference coverage | News

BE MOBILE trials support bimekizumab for the treatment of axSpA

The results of two phase 3 studies suggest that dual inhibition of IL-17A and IL-17F with bimekizumab may represent a promising treatment option for nonradiographic axial spondyloarthritis and ankylosing spondylitis.

01-06-2022 | EULAR 2022 | Conference coverage | News

SELECT-AXIS 2: Upadacitinib shows promise for axSpA

Findings from the SELECT-AXIS 2 trial provide further support for the benefits of upadacitinib across the spectrum of axial spondyloarthritis.

Expert video interviews from the EULAR 2022 Congress

20-06-2022 | EULAR 2022 | Conference coverage | Video

BE MOBILE 1 and 2: How might bimekizumab impact axSpA clinical practice?

Fabian Proft discusses the potential impact of bimekizumab on the treatment of radiographic and nonradiographic axial spondyloarthritis in light of findings from the BE MOBILE 1 and 2 trials.

15-06-2022 | EULAR 2022 | Conference coverage | Video

BE COMPLETE and BE OPTIMAL: How might bimekizumab impact PsA clinical practice?

Philippe Carron comments on the findings from the BE COMPLETE and BE OPTIMAL studies, and discusses how bimekizumab may impact the psoriatic arthritis treatment landscape if approved by the regulatory authorities.

14-06-2022 | EULAR 2022 | Conference coverage | Video

The BE MOBILE 1 and 2 trials of bimekizumab in axSpA

Désirée van der Heijde outlines the findings of two phase 3 trials demonstrating that bimekizumab may be beneficial for patients with nonradiographic axial spondyloarthritis or ankylosing spondylitis.

07-06-2022 | EULAR 2022 | Conference coverage | Video

The BE COMPLETE and BE OPTIMAL trials of bimekizumab in PsA

Joseph Merola talks about the BE COMPLETE and BE OPTIMAL trials, which showed that the dual IL-17A/IL-17F inhibitor bimekizumab is a promising treatment option for psoriatic arthritis patients with and without prior exposure to TNF inhibitors.

Latest news from the EULAR 2022 Congress

09-06-2022 | EULAR 2022 | Conference coverage | News

Reduced methotrexate dose noninferior to higher dose at adalimumab initiation in RA

08-06-2022 | EULAR 2022 | Conference coverage | News

Maternal, fetal morbidity rates remain high in SLE

08-06-2022 | EULAR 2022 | Conference coverage | News

NSAID suppression of axSpA spinal progression greatest with COX-2 selective inhibitors

07-06-2022 | EULAR 2022 | Conference coverage | News

Call for CV risk assessment when starting tofacitinib in patients with PsA

06-06-2022 | EULAR 2022 | Conference coverage | News

DMARD treatment has ‘profound anticoagulant effects’ in early RA

05-06-2022 | EULAR 2022 | Conference coverage | News

Deucravacitinib warrants further investigation for SLE

04-06-2022 | EULAR 2022 | Conference coverage | News

Sarilumab shows treatment promise in relapsing polymyalgia rheumatica

04-06-2022 | EULAR 2022 | Conference coverage | News

Mixed results for MACE risk with JAK inhibitors in RA

03-06-2022 | EULAR 2022 | Conference coverage | News